Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:37 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
The Hemophilia Inhibitor Prevention Trial
NCT04303559 · Margaret Ragni · PHASE3 · terminated · last registry update 2023-04-11 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The INHIBIT Trials IDSMB, in a letter dated 05-18-22, recommended, given the slow enrollment, that the INHIBIT Trials be discontinued due to futility.” | – | Registry record, Margaret Ragni |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against F9 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-04-04Results posted on the registry: BioMarin Pharmaceutical, valoctocogene roxaparvovec (NCT04323098)
- 2024-03-27Results posted on the registry: Pfizer, PF-06838435/ fidanacogene elaparvovec (NCT03861273)
- 2024-03-20Results posted on the registry: Indiana Hemophilia &Thrombosis Center, Inc., Emicizumab (NCT03921294)
- 2024-03-07Phase 3 first posted: Spark Therapeutics, Inc., SPK-8011 (NCT06297486)
- 2024-03-06Results posted on the registry: Hoffmann-La Roche, Emicizumab (NCT03315455)
- 2024-01-25Phase 3 first posted: BioMarin Pharmaceutical, Valoctocogene roxaparvovec (NCT06224907)
- 2024-01-05Also stopped (withdrawn): Emory University, Nuwiq (low dose protocol) + HEMLIBRA (NCT04030052)
- 2023-12-29Results posted on the registry: Novo Nordisk A/S, nonacog beta pegol (NCT02141074)
- 2023-12-05Phase 3 first posted: Chulalongkorn University, "Emicizumab", "HEMLIBRA®" (NCT06155955)
- 2023-11-28Results posted on the registry: BioMarin Pharmaceutical, valoctocogene roxaparvovec (NCT03370913)
- 2023-08-22Phase 3 first posted: CSL Behring, CSL222 (AAV5-hFIXco-Padua) (NCT06003387)
- 2023-07-20Also stopped (terminated): Spur Therapeutics, FLT180a (NCT03641703)
- 2023-07-11Results posted on the registry: HealthPartners Institute, 4-factor prothrombin complex concentrate (4FPCC) (NCT03064035)
- 2023-05-30Phase 3 first posted: Novo Nordisk A/S, NNC0365-3769 (Mim8) PPX (NCT05878938)
- 2023-03-08Results posted on the registry: The University of Texas Health Science Center, Houston, Platelet Transfusion + FFP and Cryoprecipitate (NCT03045068)
- 2023-03-08Results posted on the registry: Octapharma, Octaplex + Beriplex P/N (Kcentra) (NCT02740335)
- 2023-02-21Results posted on the registry: Margaret Ragni, Eloctate ITI + Emicizumab (NCT04303572)
- 2023-02-21Also stopped (terminated): Margaret Ragni, Eloctate ITI + Emicizumab (NCT04303572)
- 2023-02-09Results posted on the registry: Baxalta now part of Shire, FEIBA (NCT02764489)
- 2023-02-06Results posted on the registry: Genzyme, a Sanofi Company, Fitusiran + BPA prophylaxis (NCT03549871)
- 2023-01-31Results posted on the registry: Octapharma, Octaplex (human prothrombin complex concentrate) + Fresh frozen plasma (NCT00618098)
- 2022-12-22Phase 3 first posted: Sanofi, Fitusiran + Clotting factor concentrates (CFC) or bypassing agents (BPA) (NCT05662319)
- 2022-12-15Results posted on the registry: Hoffmann-La Roche, Emicizumab (NCT04158648)
- 2022-12-08Also stopped (terminated): Aspen Global Incorporated, Danaparoid Sodium + Argatroban (NCT03809481)
- 2022-12-05Also stopped (withdrawn): Mayo Clinic, FEIBA + Placebo (NCT05020483)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision